Silence Therapeutics (SLN) Stock Forecast & Price Target

Silence Therapeutics is a company with a promising drug, divesiran, which is showing positive results in phase 1 trials for a rare blood disorder. Despite its potential, the company's undervaluation may be due to risks and uncertainties surrounding the drug's development. However, experts believe that the convenience of divesiran compared to its competitors, as well as its potential to target other diseases via the hepcidin pathway, make Silence Therapeutics a strong long-term investment with a potential upside of over 175%.

Silence Therapeutics is facing significant competition from other companies developing similar drugs targeting the hepcidin pathway, and their current pipeline programs have not yet demonstrated significant and consistent efficacy in clinical trials. Furthermore, while their siRNA technology may have some advantages, it is also facing competition from other modalities such as monoclonal antibodies. Divesiran is their most promising candidate, but even if it shows comparable efficacy to competitors, its dosing frequency of every 6 weeks may not be attractive enough to physicians and patients compared to other potential treatments.